{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:32:40Z","timestamp":1793665960908,"version":"4.5.1"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12325-020-01354-6","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T08:06:00Z","timestamp":1588752360000},"page":"2604-2619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Limited Utility for Benzodiazepines in Chronic Pain Management: A Narrative Review"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-6929","authenticated-orcid":false,"given":"Steven L.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"issue":"10","key":"1354_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jpain.2008.05.005","volume":"9","author":"A Tsang","year":"2008","unstructured":"Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10):883\u201391.","journal-title":"J Pain"},{"issue":"10","key":"1354_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jpain.2014.05.009","volume":"15","author":"J Kennedy","year":"2014","unstructured":"Kennedy J, Roll JM, Schraudner T, et al. Prevalence of persistent pain in the US adult population: new data from the 2010 national health interview survey. J Pain. 2014;15(10):979\u201384.","journal-title":"J Pain"},{"issue":"15","key":"1354_CR3","doi-asserted-by":"publisher","first-page":"E2678","DOI":"10.3390\/molecules24152678","volume":"24","author":"DH Ngo","year":"2019","unstructured":"Ngo DH, Vo TS. An updated review on pharmaceutical properties of gamma-aminobutyric acid. Molecules. 2019;24(15):E2678.","journal-title":"Molecules"},{"issue":"2","key":"1354_CR4","first-page":"214","volume":"13","author":"CE Griffin","year":"2013","unstructured":"Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214\u201323.","journal-title":"Ochsner J"},{"issue":"1","key":"1354_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1124\/jpet.110.178244","volume":"337","author":"DE Earl","year":"2011","unstructured":"Earl DE, Tietz EI. Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors. J Pharmacol Exp Ther. 2011;337(1):301\u201311.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1354_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1213\/01.ANE.0000096189.70405.A5","volume":"98","author":"CS Yuan","year":"2004","unstructured":"Yuan CS, Mehendale S, Xiao Y, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg. 2004;98(2):353\u20138.","journal-title":"Anesth Analg"},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drugalcdep.2014.07.016","volume":"143","author":"JA Lile","year":"2014","unstructured":"Lile JA, Kelly TH, Hays LR. Separate and combined effects of the GABAA positive allosteric modulator diazepam and \u03949-THC in humans discriminating \u03949-THC. Drug Alcohol Depend. 2014;143:141\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1354_CR8","doi-asserted-by":"publisher","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","volume":"2","author":"SD Agarwal","year":"2019","unstructured":"Agarwal SD, Bruce E, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399.","journal-title":"JAMA Netw Open"},{"key":"1354_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","volume":"106","author":"MA Bachhuber","year":"2016","unstructured":"Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996\u20132013. Am J Pub Health. 2016;106:686\u20138.","journal-title":"Am J Pub Health"},{"issue":"6","key":"1354_CR10","doi-asserted-by":"publisher","first-page":"1812174","DOI":"10.4088\/JCP.18m12174","volume":"79","author":"C Blanco","year":"2018","unstructured":"Blanco C, Han B, Jones CM, et al. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. J Clin Psychiatry. 2018;79(6):1812174.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1354_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","volume":"70","author":"DT Maust","year":"2019","unstructured":"Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97\u2013106.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"1354_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7326\/M18-1243","volume":"169","author":"ASB Bohnert","year":"2018","unstructured":"Bohnert ASB, Guy GP, Losby JL. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention's 2016 Opioid Guideline. Ann Intern Med. 2018;169(6):367\u201375.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1354_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7326\/M18-0852","volume":"169","author":"R Carico","year":"2018","unstructured":"Carico R, Zhao X, Thorpe CT, et al. Receipt of overlapping opioid and benzodiazepine prescriptions among veterans dually enrolled in Medicare Part D and the Department of Veterans Affairs: a cross-sectional study. Ann Intern Med. 2018;169(9):593\u2013601.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1354_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.amepre.2019.06.007","volume":"57","author":"G Guy","year":"2019","unstructured":"Guy G, Zhang K, Halpin J, Sargent W. An examination of concurrent opioid and benzodiazepine prescribing in 9 states, 2015. Am J Prevent Med. 2019;57(5):629\u201336.","journal-title":"Am J Prevent Med"},{"issue":"2","key":"1354_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","volume":"51","author":"CS Hwang","year":"2016","unstructured":"Hwang CS, Kang EM, Kornegay CJ, et al. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002\u20132014. Am J Prev Med. 2016;51(2):151\u201360.","journal-title":"Am J Prev Med"},{"issue":"6","key":"1354_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/ADM.0000000000000354","volume":"11","author":"FL McClure","year":"2017","unstructured":"McClure FL, Niles JK, Kaufman HW, Gudin J. Concurrent use of opioids and benzodiazepines: evaluation of prescription drug monitoring by a United States laboratory. J Addict Med. 2017;11(6):420\u20136.","journal-title":"J Addict Med"},{"key":"1354_CR17","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","volume":"356","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.","journal-title":"BMJ"},{"issue":"2","key":"1354_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/pme.12594","volume":"16","author":"S Nielsen","year":"2015","unstructured":"Nielsen S, Lintzeris N, Bruno R, et al. Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization. Pain Med. 2015;16(2):356\u201366.","journal-title":"Pain Med"},{"issue":"6","key":"1354_CR19","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/pm\/pny179","volume":"20","author":"BJH Yarborough","year":"2019","unstructured":"Yarborough BJH, Stumbo SP, Stoneburner A, et al. Correlates of benzodiazepine use and adverse outcomes among patients with chronic pain prescribed long-term opioid therapy. Pain Med. 2019;20(6):1148\u201355.","journal-title":"Pain Med"},{"key":"1354_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pmedr.2017.12.010","volume":"9","author":"ME Hirschtritta","year":"2018","unstructured":"Hirschtritta ME, Delucchib KL, Olfson M. Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993\u20132014. Prevent Med Rep. 2018;9:49\u2013544.","journal-title":"Prevent Med Rep"},{"key":"1354_CR21","first-page":"1","volume":"166","author":"LH Chen","year":"2014","unstructured":"Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths Involving opioid analgesics: United States, 1999\u20132011. NCHS Data Brief. 2014;166:1\u20138.","journal-title":"NCHS Data Brief"},{"issue":"34","key":"1354_CR22","first-page":"945","volume":"67","author":"CL Mattson","year":"2018","unstructured":"Mattson CL, O\u2019Donnell J, Kariisa M, et al. Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 states, July 2016\u2013June 2017. MMWR. 2018;67(34):945\u201351.","journal-title":"MMWR"},{"issue":"1","key":"1354_CR23","first-page":"85","volume":"17","author":"N Dasgupta","year":"2016","unstructured":"Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85\u2013988.","journal-title":"Pain Med"},{"key":"1354_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s11606-016-3740-0","volume":"31","author":"DS Kroll","year":"2016","unstructured":"Kroll DS, Niece HR, Barsky AJ, Linder JA. Benzodiazepines are prescribed more frequently to patients already at risk for benzodiazepine-related adverse events in primary care. J Gen Intern Med. 2016;31:1027\u201334.","journal-title":"J Gen Intern Med"},{"key":"1354_CR25","unstructured":"US Food and Drug Administration. FDA News Release: FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. 2016. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine. Accessed 5 Apr 2020."},{"issue":"9 Suppl 3","key":"1354_CR26","first-page":"S15","volume":"102","author":"FJ Goldstein","year":"2002","unstructured":"Goldstein FJ. Adjuncts to opioid therapy. J Am Osteopath Assoc. 2002;102(9 Suppl 3):S15\u201321.","journal-title":"J Am Osteopath Assoc"},{"issue":"8","key":"1354_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/0885-3924(94)90112-0","volume":"9","author":"S Reddy","year":"1994","unstructured":"Reddy S, Patt RB. The benzodiazepines as adjuvant analgesics. J Pain Symptom Manage. 1994;9(8):510\u20134.","journal-title":"J Pain Symptom Manage"},{"issue":"11","key":"1354_CR28","first-page":"1435","volume":"15","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Portnoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology. 2001;15(11):1435\u201342 (1445; Abstract).","journal-title":"Oncology"},{"issue":"1\u20132","key":"1354_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2011.03.017","volume":"61","author":"G Munro","year":"2011","unstructured":"Munro G, Erichsen HK, Rae MG, Mirza NR. A question of balance - positive versus negative allosteric modulation of GABAA receptor subtypes as a driver of analgesic efficacy in rat models of inflammatory and neuropathic pain. Neuropharmacology. 2011;61(1\u20132):121\u201332.","journal-title":"Neuropharmacology"},{"issue":"4","key":"1354_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/1568026799078787","volume":"12","author":"ML Trincavelli","year":"2012","unstructured":"Trincavelli ML, Da Pozzo E, Daniele S, Martini C. The GABAA-BZR complex as target for the development of anxiolytic drugs. Curr Top Med Chem. 2012;12(4):254\u201369.","journal-title":"Curr Top Med Chem"},{"key":"1354_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.brainres.2009.06.043","volume":"1286","author":"H Hernstadt","year":"2009","unstructured":"Hernstadt H, Wang S, Lim G, Mao J. Spinal translocator protein (TSPO) modulates pain behavior in rats with CFA-induced monoarthritis. Brain Res. 2009;1286:42\u201352.","journal-title":"Brain Res"},{"issue":"4","key":"1354_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1042\/BST20150028","volume":"43","author":"E Da Pozzo","year":"2015","unstructured":"Da Pozzo E, Giacomelli C, Barresi E, et al. Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. Biochem Soc Trans. 2015;43(4):559\u201365.","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"1354_CR33","doi-asserted-by":"publisher","first-page":"E1694","DOI":"10.3390\/ijms19061694","volume":"19","author":"F Bonsack","year":"2018","unstructured":"Bonsack F, Sukumari-Ramesh S. TSPO: an evolutionarily conserved protein with elusive functions. Int J Mol Sci. 2018;19(6):E1694.","journal-title":"Int J Mol Sci"},{"key":"1354_CR34","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1152\/physrev.00011.2002","volume":"82","author":"LR Watkins","year":"2002","unstructured":"Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002;82:981\u20131011.","journal-title":"Physiol Rev"},{"issue":"1","key":"1354_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4077\/CJP.2016.BAD332","volume":"59","author":"SL Chen","year":"2016","unstructured":"Chen SL, Zang Y, Zheng WH, et al. Inhibition of neuropathic pain by a single intraperitoneal injection of diazepam in the rat: possible role of neurosteroids. Chin J Physiol. 2016;59(1):9\u201320.","journal-title":"Chin J Physiol"},{"issue":"2","key":"1354_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ejp.907","volume":"21","author":"C Abdel Shaheed","year":"2017","unstructured":"Abdel Shaheed C, Maher CG, Williams KA, McLachlan AJ. Efficacy and tolerability of muscle relaxants for low back pain: systematic review and meta-analysis. Eur J Pain. 2017;21(2):228\u201337.","journal-title":"Eur J Pain"},{"issue":"7","key":"1354_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.7326\/M16-2458","volume":"166","author":"R Chou","year":"2017","unstructured":"Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann Int Med. 2017;166(7):480\u201392.","journal-title":"Ann Int Med"},{"key":"1354_CR38","unstructured":"Chou R, Deyo R, Friedly J, et al. Noninvasive treatments for low back pain. Comparative Effectiveness Review No. 169. AHRQ Publication No. 16-EHC004-EF. Rockville, MD: Agency for Healthcare Research and Quality. 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK350276\/. Accessed 5 Apr 2020."},{"issue":"2","key":"1354_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/014107689108400206","volume":"84","author":"PG Hardo","year":"1991","unstructured":"Hardo PG, Kennedy TD. Night sedation and arthritic pain. J R Soc Med. 1991;84(2):73\u20135.","journal-title":"J R Soc Med"},{"key":"1354_CR40","first-page":"CD008922","volume":"1","author":"BL Richards","year":"2012","unstructured":"Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008922.","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"1354_CR41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1001\/jama.1981.03320140056031","volume":"246","author":"LE Hollister","year":"1981","unstructured":"Hollister LE, Conley FK, Britt RH, Shuer L. Long-term use of diazepam. JAMA. 1981;246(14):1568\u201370.","journal-title":"JAMA"},{"issue":"2","key":"1354_CR42","first-page":"139","volume":"11","author":"E Singer","year":"1997","unstructured":"Singer E, Dionne R. A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. J Orofac Pain. 1997;11(2):139\u201346.","journal-title":"J Orofac Pain"},{"issue":"10","key":"1354_CR43","first-page":"1313","volume":"37","author":"JK Elenbaas","year":"1980","unstructured":"Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980;37(10):1313\u201323.","journal-title":"Am J Hosp Pharm"},{"issue":"6","key":"1354_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/030006058100900613","volume":"9","author":"Z Fryda-Kaurimsky","year":"1981","unstructured":"Fryda-Kaurimsky Z, M\u00fcller-Fassbender H. Tizanidine (DS 103\u2013282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam. J Int Med Res. 1981;9(6):501\u20135.","journal-title":"J Int Med Res"},{"issue":"1","key":"1354_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/030006058100900111","volume":"9","author":"OL Hennies","year":"1981","unstructured":"Hennies OL. A new skeletal muscle relaxant (DS 103\u2013282) compared to diazepam in the treatment of muscle spasm of local origin. J Int Med Res. 1981;9(1):62\u20138.","journal-title":"J Int Med Res"},{"issue":"2","key":"1354_CR46","first-page":"216","volume":"10","author":"WA Katz","year":"1988","unstructured":"Katz WA, Dube J. Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience. Clin Ther. 1988;10(2):216\u201328.","journal-title":"Clin Ther"},{"issue":"3","key":"1354_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/08869634.1990.11678317","volume":"8","author":"JR Stanko","year":"1990","unstructured":"Stanko JR. Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner. Cranio. 1990;8(3):234\u201343.","journal-title":"Cranio"},{"issue":"6","key":"1354_CR48","first-page":"398","volume":"18","author":"MJ Schneider","year":"1995","unstructured":"Schneider MJ. Tender points\/fibromyalgia vs trigger points\/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. J Manipulative Physiol Ther. 1995;18(6):398\u2013406.","journal-title":"J Manipulative Physiol Ther"},{"issue":"1","key":"1354_CR49","first-page":"64","volume":"16","author":"CR Herman","year":"2002","unstructured":"Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain. 2002;16(1):64\u201370.","journal-title":"J Orofac Pain"},{"issue":"6","key":"1354_CR50","first-page":"944","volume":"19","author":"F Wolfe","year":"1992","unstructured":"Wolfe F, Simons DG, Friction J, et al. The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J Rheumatol. 1992;19(6):944\u201351.","journal-title":"J Rheumatol"},{"issue":"1","key":"1354_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1515\/sjpain-2019-0054","volume":"20","author":"F Wolfe","year":"2019","unstructured":"Wolfe F, Butler SH, Fitzcharles M, et al. Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. Scand J Pain. 2019;20(1):77\u201386.","journal-title":"Scand J Pain"},{"issue":"15","key":"1354_CR52","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2014.3266","volume":"311","author":"DJ Clauw","year":"2014","unstructured":"Clauw DJ. Fibromyalgia: clinical review. JAMA. 2014;311(15):1547\u201355.","journal-title":"JAMA"},{"key":"1354_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2474-8-27","volume":"8","author":"RM Bennett","year":"2007","unstructured":"Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"1354_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1300\/J094v02n01_02","volume":"2","author":"HM Kravitz","year":"1994","unstructured":"Kravitz HM, Katz RS, Helmke N, et al. Alprazolam and ibuprofen in the treatment of fibromyalgia - report of a double-blind placebo-controlled study. J Musculoskeletal Pain. 1994;2(1):3\u201327.","journal-title":"J Musculoskeletal Pain"},{"issue":"3","key":"1354_CR55","first-page":"529","volume":"23","author":"H Moldofsky","year":"1996","unstructured":"Moldofsky H, Lue FA, Mously C, et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol. 1996;23(3):529\u201333.","journal-title":"J Rheumatol"},{"key":"1354_CR56","first-page":"CD..9486","volume":"5","author":"R Corrigan","year":"2012","unstructured":"Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;5:CD.9486.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1354_CR57","first-page":"10567","volume":"2013","author":"PJ Wiffen","year":"2013","unstructured":"Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;2013(11):10567.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"1354_CR58","first-page":"e427","volume":"7","author":"AB Bhatti","year":"2015","unstructured":"Bhatti AB, Gazali ZA. Recent advances and review on treatment of stiff person syndrome in adults and pediatric patients. Cureus. 2015;7(12):e427.","journal-title":"Cureus"},{"issue":"5","key":"1354_CR59","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/jnnp.65.5.633","volume":"65","author":"RA Barker","year":"1998","unstructured":"Barker RA, Revesz T, Thom M, et al. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 1998;65(5):633\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1354_CR60","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s004150050425","volume":"246","author":"P Brown","year":"1999","unstructured":"Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol. 1999;246(8):648\u201352.","journal-title":"J Neurol"},{"issue":"10","key":"1354_CR61","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4088\/JCP.v58n1007","volume":"58","author":"JA Tinsley","year":"1997","unstructured":"Tinsley JA, Barth EM, Black JL, Williams DE. Psychiatric consultations in stiff-man syndrome. J Clin Psychiatry. 1997;58(10):444\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1354_CR62","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/jnnp.74.4.462","volume":"74","author":"P Henningsen","year":"2003","unstructured":"Henningsen P, Meinck HM. Specific phobia is a frequent non-motor feature in stiff man syndrome. J Neurol Neurosurg Psychiatry. 2003;74(4):462\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1354_CR63","doi-asserted-by":"publisher","unstructured":"Souissi MA, Bellakhal S, Gharbi E, et al. A stiff person syndrome misdiagnosed as a psychiatric illness. Curr Rheumatol Rev. 2019. https:\/\/doi.org\/10.2174\/1573397115666191116101240.","DOI":"10.2174\/1573397115666191116101240"},{"key":"1354_CR64","first-page":"7431092","volume":"2017","author":"CE Cervantes","year":"2017","unstructured":"Cervantes CE, Lee Lau H, Binazir TA, et al. Why it is not always anxiety: a tough diagnosis of stiff person syndrome. Case Rep Neurol Med. 2017;2017:7431092.","journal-title":"Case Rep Neurol Med"},{"issue":"23","key":"1354_CR65","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1097\/MD.0000000000000954","volume":"94","author":"P Zdziarski","year":"2015","unstructured":"Zdziarski P. A case of stiff person syndrome: immunomodulatory effect of benzodiazepines: successful rituximab and tizanidine therapy. Medicine (Baltimore). 2015;94(23):e954.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1354_CR66","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/dmcn.13652","volume":"60","author":"D Fehlings","year":"2018","unstructured":"Fehlings D, Brown L, Harvey A, et al. Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Dev Med Child Neurol. 2018;60(4):356\u201366.","journal-title":"Dev Med Child Neurol"},{"issue":"1\u20132","key":"1354_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","volume":"25","author":"E Chang","year":"2013","unstructured":"Chang E, Ghosh N, Yanni D, et al. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25(1\u20132):11\u201322.","journal-title":"Crit Rev Phys Rehabil Med"},{"issue":"2","key":"1354_CR68","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1185\/030079908X261113","volume":"24","author":"L Kamen","year":"2008","unstructured":"Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 2008;24(2):425\u201339.","journal-title":"Curr Med Res Opin"},{"key":"1354_CR69","first-page":"10362","volume":"10","author":"C Lindsay","year":"2016","unstructured":"Lindsay C, Kouzouna A, Simcox C, Pandyan AD. Pharmacological interventions other than botulinum toxin for spasticity after stroke. Cochrane Database Syst Rev. 2016;10:10362.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1354_CR70","first-page":"5","volume":"42","author":"M Taricco","year":"2006","unstructured":"Taricco M, Pagliacci MC, Telaro E, Adone R. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys. 2006;42(1):5\u201315.","journal-title":"Eura Medicophys"},{"issue":"40","key":"1354_CR71","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta7400","volume":"7","author":"S Beard","year":"2003","unstructured":"Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii (ix\u2013x, 1\u2013111).","journal-title":"Health Technol Assess"},{"issue":"10","key":"1354_CR72","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1185\/03007998809111122","volume":"10","author":"A Bes","year":"1988","unstructured":"Bes A, Eyssette M, Pierrot-Deseilligny E, et al. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin. 1988;10(10):709\u201318.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"1354_CR73","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1177\/1352458516643600","volume":"22","author":"S Otero-Romero","year":"2016","unstructured":"Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler. 2016;22(11):1386\u201396.","journal-title":"Mult Scler"},{"key":"1354_CR74","first-page":"170","volume":"12","author":"A Glass","year":"1974","unstructured":"Glass A, Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia. 1974;12:170\u20134.","journal-title":"Paraplegia"},{"issue":"4","key":"1354_CR75","first-page":"241","volume":"15","author":"L Groves","year":"1998","unstructured":"Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998;15(4):241\u201351.","journal-title":"Adv Ther"},{"key":"1354_CR76","first-page":"278","volume":"4","author":"M Roussan","year":"1985","unstructured":"Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica. 1985;4:278\u201384.","journal-title":"Pharmatherapeutica"},{"issue":"6","key":"1354_CR77","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/0269215517745348","volume":"32","author":"X Fu","year":"2018","unstructured":"Fu X, Wang Y, Wang C, et al. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil. 2018;32(6):713\u201321.","journal-title":"Clin Rehabil"},{"issue":"2","key":"1354_CR78","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1354_CR79","first-page":"9486","volume":"2012","author":"R Corrigan","year":"2012","unstructured":"Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;2012(5):9486.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1354_CR80","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1212\/WNL.38.9.1427","volume":"38","author":"MB Max","year":"1988","unstructured":"Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988;38(9):1427\u201332.","journal-title":"Neurology"},{"issue":"10","key":"1354_CR81","first-page":"1245","volume":"70","author":"C Solaro","year":"2010","unstructured":"Solaro C, Uccelli MM. Pharmacological management of pain in patients with multiple sclerosis. Drugs. 2010;70(10):1245\u201354.","journal-title":"Drugs"},{"key":"1354_CR82","first-page":"641","volume":"44","author":"R Shukla","year":"1996","unstructured":"Shukla R, Nag D, Ahuja RC. Alprazolam in chronic tension type headache. J Assoc Physicians India. 1996;44:641\u20134.","journal-title":"J Assoc Physicians India"},{"issue":"2","key":"1354_CR83","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/fampra\/cmp089","volume":"27","author":"AP Verhagen","year":"2010","unstructured":"Verhagen AP, Damen L, Berger MY, et al. Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review. Fam Pract. 2010;27(2):151\u201365.","journal-title":"Fam Pract"},{"key":"1354_CR84","first-page":"1205","volume":"2009","author":"A Krishnan","year":"2009","unstructured":"Krishnan A, Silver N. Headache (chronic tension-type). BMJ Clin Evid. 2009;2009:1205.","journal-title":"BMJ Clin Evid"},{"issue":"11","key":"1354_CR85","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/014107688708001110","volume":"80","author":"GI Hackett","year":"1987","unstructured":"Hackett GI, Boddie HG, Harrison P. Chronic muscle contraction headache: the importance of depression and anxiety. J R Soc Med. 1987;80(11):689\u201391.","journal-title":"J R Soc Med"},{"issue":"10","key":"1354_CR86","first-page":"4715","volume":"2010","author":"HR Mujakperuo","year":"2010","unstructured":"Mujakperuo HR, Watson M, Morrison R, Macfarlane TV. Pharmacological interventions for pain in patients with temporomandibular disorders. Cochrane Database Syst Rev. 2010;2010(10):4715.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1354_CR87","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00002508-200201000-00004","volume":"18","author":"SH Sindrup","year":"2002","unstructured":"Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain. 2002;18(1):22\u20137.","journal-title":"Clin J Pain"},{"issue":"5","key":"1354_CR88","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.tripleo.2011.01.033","volume":"111","author":"WJ Martin","year":"2011","unstructured":"Martin WJ, Forouzanfar T. The efficacy of anticonvulsants on orofacial pain: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(5):627\u201333.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"6","key":"1354_CR89","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/odi.12422","volume":"22","author":"Y Cui","year":"2016","unstructured":"Cui Y, Xu H, Chen FM, et al. Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis. Oral Dis. 2016;22(6):503\u201311.","journal-title":"Oral Dis"},{"issue":"2","key":"1354_CR90","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.ebd.6401244","volume":"18","author":"DK Fischoff","year":"2017","unstructured":"Fischoff DK, Spivakovsky S. Little evidence to support or refute interventions for the management of burning mouth syndrome. Evid Based Dent. 2017;18(2):57\u20138.","journal-title":"Evid Based Dent"},{"issue":"3","key":"1354_CR91","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/odi.12660","volume":"24","author":"YF Liu","year":"2018","unstructured":"Liu YF, Kim Y, Yoo T, et al. Burning mouth syndrome: a systematic review of treatments. Oral Dis. 2018;24(3):325\u201334.","journal-title":"Oral Dis"},{"issue":"4","key":"1354_CR92","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1834-7819.2009.01154.x","volume":"54","author":"KE Barker","year":"2009","unstructured":"Barker KE, Batstone MD, Savage NW. Comparison of treatment modalities in burning mouth syndrome. Aust Dent J. 2009;54(4):300\u20135.","journal-title":"Aust Dent J"},{"issue":"1","key":"1354_CR93","first-page":"19","volume":"49","author":"R de Rivera","year":"2010","unstructured":"de Rivera R, Campillo E, L\u00f3pez-L\u00f3pez J, Chimenos-K\u00fcstner E. Response to topical clonazepam in patients with burning mouth syndrome: a clinical study. Bull Group Int Rech Sci Stomatol Odontol. 2010;49(1):19\u201329.","journal-title":"Bull Group Int Rech Sci Stomatol Odontol"},{"issue":"2","key":"1354_CR94","first-page":"125","volume":"25","author":"K Amos","year":"2011","unstructured":"Amos K, Yeoh SC, Farah CS. Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: a retrospective pilot study. J Orofac Pain. 2011;25(2):125\u201330.","journal-title":"J Orofac Pain"},{"issue":"11","key":"1354_CR95","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.ijom.2017.03.032","volume":"46","author":"M Fenelon","year":"2017","unstructured":"Fenelon M, Quinque E, Arrive E, et al. Pain-relieving effects of clonazepam and amitriptyline in burning mouth syndrome: a retrospective study. Int J Oral Maxillofac Surg. 2017;46(11):1505\u201311.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"4","key":"1354_CR96","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/acupmed-2015-010759","volume":"33","author":"A Jurisic Kvesic","year":"2015","unstructured":"Jurisic Kvesic A, Zavoreo I, Basic Kes V, et al. The effectiveness of acupuncture versus clonazepam in patients with burning mouth syndrome. Acupunct Med. 2015;33(4):289\u201392.","journal-title":"Acupunct Med"},{"issue":"4","key":"1354_CR97","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10103-016-1897-8","volume":"31","author":"PG Arduino","year":"2016","unstructured":"Arduino PG, Cafaro A, Garrone M, et al. A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome. Lasers Med Sci. 2016;31(4):811\u20136.","journal-title":"Lasers Med Sci"},{"issue":"6","key":"1354_CR98","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.semarthrit.2007.09.003","volume":"37","author":"MB Yunus","year":"2008","unstructured":"Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. 2008;37(6):339\u201352.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1354_CR99","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2174\/157339711102150702112236","volume":"11","author":"MB Yunus","year":"2015","unstructured":"Yunus MB. Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology. Curr Rheumatol Rev. 2015;11(2):70\u201385.","journal-title":"Curr Rheumatol Rev"},{"issue":"2","key":"1354_CR100","doi-asserted-by":"publisher","first-page":"e42747","DOI":"10.5812\/aapm.42747","volume":"7","author":"L Chen","year":"2017","unstructured":"Chen L, Ilham SJ, Feng B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth Pain Med. 2017;7(2):e42747.","journal-title":"Anesth Pain Med"},{"issue":"9","key":"1354_CR101","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1517\/14656566.2013.794223","volume":"14","author":"M Camilleri","year":"2013","unstructured":"Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2013;14(9):1151\u201360.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"1354_CR102","first-page":"129","volume":"141","author":"G Mollica","year":"1992","unstructured":"Mollica G, Manno G. Otilonium bromide-diazepam in the treatment of the irritable colon. A controlled study versus otilonium bromide. Clin Ter. 1992;141(8):129\u201334.","journal-title":"Clin Ter"},{"issue":"Suppl 8","key":"1354_CR103","first-page":"38","volume":"62","author":"RB Lydiard","year":"2001","unstructured":"Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry. 2001;62(Suppl 8):38\u201345.","journal-title":"J Clin Psychiatry"},{"issue":"38","key":"1354_CR104","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.3748\/wjg.v17.i38.4251","volume":"17","author":"P Salari","year":"2011","unstructured":"Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol. 2011;17(38):4251\u20137.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1354_CR105","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11938-004-0014-4","volume":"7","author":"YA Saito","year":"2004","unstructured":"Saito YA, Fox JC. Management of functional abdominal pain. Curr Treat Options Gastroenterol. 2004;7(4):279\u201390.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"3","key":"1354_CR106","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-016-0687-8","volume":"77","author":"ET Carey","year":"2017","unstructured":"Carey ET, Till SR, As-Sanie S. Pharmacological management of chronic pelvic pain in women. Drugs. 2017;77(3):285\u2013301.","journal-title":"Drugs"},{"issue":"40","key":"1354_CR107","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.3748\/wjg.v17.i40.4447","volume":"17","author":"G Chiarioni","year":"2011","unstructured":"Chiarioni G, Asteria C, Whitehead WE. Chronic proctalgia and chronic pelvic pain syndromes: new etiologic insights and treatment options. World J Gastroenterol. 2011;17(40):4447\u201355.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1354_CR108","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00192-013-2108-9","volume":"24","author":"CC Crisp","year":"2013","unstructured":"Crisp CC, Vaccaro CM, Estanol MV, et al. Intra-vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. Int Urogynecol J. 2013;24(11):1915\u201323.","journal-title":"Int Urogynecol J"},{"issue":"6","key":"1354_CR109","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archpsyc.1993.01820180069007","volume":"50","author":"PJ Schmidt","year":"1993","unstructured":"Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1993;50(6):467\u201373.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1354_CR110","first-page":"688","volume":"63","author":"MA Sagheer","year":"2013","unstructured":"Sagheer MA, Khan MF, Sharif S. Association between chronic low back pain, anxiety and depression in patients at a tertiary care center. J Pak Med Assoc. 2013;63(6):688\u201390.","journal-title":"J Pak Med Assoc"},{"issue":"5","key":"1354_CR111","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00586-010-1661-x","volume":"20","author":"SM Alsaadi","year":"2011","unstructured":"Alsaadi SM, McAuley JH, Hush JM, Maher CG. Prevalence of sleep disturbance in patients with low back pain. Eur Spine J. 2011;20(5):737\u201343.","journal-title":"Eur Spine J"},{"key":"1354_CR112","unstructured":"Askgaard G, Potteg\u00e5rd A, Fink-Jensen A. Benzodiazepines should still be first-line treatment for alcohol withdrawal. Ugeskr Laeger. 2017;179(3):V07160465.."},{"key":"1354_CR113","doi-asserted-by":"crossref","unstructured":"Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014;(9):CD003723. .","DOI":"10.1002\/14651858.CD003723.pub3"},{"issue":"4","key":"1354_CR114","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1345\/aph.1Q525","volume":"46","author":"S Devabhakthuni","year":"2012","unstructured":"Devabhakthuni S, Armahizer MJ, Dasta JF, Kane-Gill SL. Analgosedation: a paradigm shift in intensive care unit sedation practice. Ann Pharmacother. 2012;46(4):530\u201340.","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"1354_CR115","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00131746-200511001-00002","volume":"11","author":"MH Allen","year":"2005","unstructured":"Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005;11(Suppl 1):5\u2013108 (quiz 110\u20132).","journal-title":"J Psychiatr Pract"},{"issue":"3","key":"1354_CR116","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/M14-2841","volume":"163","author":"JM Trauer","year":"2015","unstructured":"Trauer JM, Qian MY, Doyle JS, et al. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(3):191\u2013204.","journal-title":"Ann Intern Med"},{"key":"1354_CR117","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.smrv.2014.11.007","volume":"23","author":"JM Geiger-Brown","year":"2015","unstructured":"Geiger-Brown JM, Rogers VE, Liu W, et al. Cognitive behavioral therapy in persons with comorbid insomnia: a meta-analysis. Sleep Med Rev. 2015;23:54\u201367.","journal-title":"Sleep Med Rev"},{"key":"1354_CR118","unstructured":"[No authors listed]. Sleep complaints: whenever possible, avoid the use of sleeping pills. Prescrire Int. 2008;17(97):206\u201312."},{"issue":"2","key":"1354_CR119","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307\u201349.","journal-title":"J Clin Sleep Med"},{"key":"1354_CR120","unstructured":"National Institute for Health and Clinical Excellence: Guidance. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care: pharmacological update of clinical guideline 20. 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK247130\/. Accessed 5 Apr 2020."},{"issue":"3","key":"1354_CR121","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11606-006-0021-3","volume":"22","author":"JM Cook","year":"2007","unstructured":"Cook JM, Marshall R, Masci C, Coyne JC. Physicians\u2019 perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med. 2007;22(3):303\u20137. https:\/\/doi.org\/10.1007\/s11606-006-0021-3.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"1354_CR122","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.amjopharm.2009.03.001","volume":"7","author":"MD Buck","year":"2009","unstructured":"Buck MD, Atreja A, Brunker CP, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Am J Geriatr Pharmacother. 2009;7(2):84\u201392.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"7","key":"1354_CR123","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","volume":"74","author":"GA Bushnell","year":"2017","unstructured":"Bushnell GA, St\u00fcrmer T, Gaynes BN, et al. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001\u20132014. JAMA Psychiatry. 2017;74(7):747\u201355.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"1354_CR124","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0013-7006(07)91556-0","volume":"33","author":"A P\u00e9lissolo","year":"2007","unstructured":"P\u00e9lissolo A, Maniere F, Boutges B, et al. Anxiety and depressive disorders in 4,425 long term benzodiazepine users in general practice. Encephale. 2007;33(1):32\u20138.","journal-title":"Encephale"},{"issue":"2","key":"1354_CR125","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1465-3362.2012.00496.x","volume":"32","author":"J Ilom\u00e4ki","year":"2013","unstructured":"Ilom\u00e4ki J, Gnjidic D, Hilmer SN, et al. Psychotropic drug use and alcohol drinking in community-dwelling older Australian men: the CHAMP study. Drug Alcohol Rev. 2013;32(2):218\u201322.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"1354_CR126","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pnpbp.2008.12.004","volume":"33","author":"W Berger","year":"2009","unstructured":"Berger W, Mendlowicz MV, Marques-Portella C, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):169\u201380.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"1354_CR127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","volume":"28","author":"B Dell\u2019osso","year":"2013","unstructured":"Dell\u2019osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28(1):7\u201320.","journal-title":"Eur Psychiatry"},{"key":"1354_CR128","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Substance-related and addictive disorders. In: Diagnostic and statistical manual of mental disorders, 5th Edition. Arlington: American Psychiatric Association. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1354_CR129","first-page":"CD11170","volume":"10","author":"H Imai","year":"2016","unstructured":"Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. Cochrane Database Syst Rev. 2016;10:CD11170.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1354_CR130","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1017\/S0033291702007079","volume":"33","author":"RC Durham","year":"2003","unstructured":"Durham RC, Chambers JA, MacDonald RR, et al. Does cognitive-behavioral therapy influence the long-term outcome of generalized anxiety disorder? An 8\u201314 year follow-up of two clinical trials. Psychol Med. 2003;33(3):499\u2013509.","journal-title":"Psychol Med"},{"issue":"1","key":"1354_CR131","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1037\/0022-006X.58.1.77","volume":"58","author":"JS Klosko","year":"1990","unstructured":"Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavior therapy in treatment of panic disorder. J Consult Clin Psychol. 1990;58(1):77\u201384.","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"1354_CR132","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/00005053-199602000-00015","volume":"184","author":"AJ van Balkom","year":"1996","unstructured":"van Balkom AJ, de Beurs E, Koele P, et al. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. J Nerv Ment Dis. 1996;184(2):133\u20135.","journal-title":"J Nerv Ment Dis"},{"issue":"13","key":"1354_CR133","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1177\/1049732317728053","volume":"27","author":"AM Fixsen","year":"2017","unstructured":"Fixsen AM, Ridge D. Stories of hell and healing: internet users\u2019 construction of benzodiazepine distress and withdrawal. Qual Health Res. 2017;27(13):2030\u201341.","journal-title":"Qual Health Res"},{"key":"1354_CR134","unstructured":"Pittman CM, Youngs W, Karle E. Social networking and benzodiazepine withdrawal: the realities of dependence and the necessity of support. In: Presented at the 33rd Annual National Conference of the Anxiety and Depression Association of America, La Jolla, California. 2013. https:\/\/adaa.org\/sites\/default\/files\/Pittman121.pdf. Accessed 5 Apr 2020."},{"key":"1354_CR135","unstructured":"Young A. Survey of benzodiazepine withdrawal outcomes of an internet benzodiazepine group. 2007. http:\/\/www.benzosupport.org\/survey_contents.htm. Accessed 5 Apr 2020."},{"issue":"3","key":"1354_CR136","first-page":"391","volume":"27","author":"MK Romach","year":"1991","unstructured":"Romach MK, Busto UE, Sobell LC, et al. Long-term alprazolam use: abuse, dependence or treatment? Psychopharmacol Bull. 1991;27(3):391\u20135.","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"1354_CR137","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1528-1157.1989.tb05326.x","volume":"30","author":"U Specht","year":"1989","unstructured":"Specht U, Boenigk HE, Wolf P. Discontinuation of clonazepam after long-term treatment. Epilepsia. 1989;30(4):458\u201363.","journal-title":"Epilepsia"},{"issue":"1","key":"1354_CR138","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0278-5846(88)90066-8","volume":"12","author":"GA Fava","year":"1988","unstructured":"Fava GA. Fading of therapeutic effects of alprazolam in agoraphobia. Case reports. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(1):109\u201312.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1354_CR139","unstructured":"Ashton H. The Ashton manual: benzodiazepines\u2014how they work and how to withdraw. 2002. https:\/\/www.benzo.org.uk\/manual\/. Accessed 5 Apr 2020."},{"key":"1354_CR140","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1360-0443.1987.tb01529.x","volume":"82","author":"H Ashton","year":"1987","unstructured":"Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict. 1987;82:655\u201371.","journal-title":"Br J Addict"},{"issue":"4","key":"1354_CR141","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","volume":"17","author":"J Brandt","year":"2017","unstructured":"Brandt J, Leong C. Benzodiazepines and Z-Drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D. 2017;17(4):493\u2013507.","journal-title":"Drugs R D"},{"issue":"2\u20133","key":"1354_CR142","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.drugalcdep.2007.04.009","volume":"90","author":"WC Becker","year":"2007","unstructured":"Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse and dependence on sedatives and tranquilizers among US adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend. 2007;90(2\u20133):280\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"1354_CR143","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/pds.1417","volume":"16","author":"AM Hausken","year":"2007","unstructured":"Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Saf. 2007;16(8):913\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1354_CR144","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.16r02037","author":"TJ Dodds","year":"2017","unstructured":"Dodds TJ. Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord. 2017. https:\/\/doi.org\/10.4088\/PCC.16r02037","journal-title":"Prim Care Companion CNS Disord"},{"issue":"1","key":"1354_CR145","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","volume":"18","author":"MJ Barker","year":"2004","unstructured":"Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37\u201348.","journal-title":"CNS Drugs"},{"issue":"2","key":"1354_CR146","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1532-5415.2005.00571.x","volume":"54","author":"SL Gray","year":"2006","unstructured":"Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc. 2006;54(2):224\u201330.","journal-title":"J Am Geriatr Soc"},{"key":"1354_CR147","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1136\/bmj.g5205","volume":"349","author":"S Billioti de Gage","year":"2014","unstructured":"Billioti de Gage S, Boride Y, Ducret T, et al. Benzodiazepine use and risk of Alzheimer\u2019s disease: case-control study. BMJ. 2014;349:5205.","journal-title":"BMJ"},{"issue":"6","key":"1354_CR148","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.1097\/MD.0000000000000483","volume":"94","author":"U Iqbal","year":"2015","unstructured":"Iqbal U, Nguyen P-A, Syed-Abdul S, et al. Is long-term use of benzodiazepine a risk for cancer? Medicine (Baltimore). 2015;94(6):e483.","journal-title":"Medicine (Baltimore)"},{"key":"1354_CR149","doi-asserted-by":"publisher","first-page":"e000850","DOI":"10.1136\/bmjopen-2012-000850","volume":"2","author":"DF Kripke","year":"2012","unstructured":"Kripke DF, Langer RD, Kline LE. Hypnotics\u2019 association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2:e000850.","journal-title":"BMJ Open"},{"issue":"10","key":"1354_CR150","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","volume":"47","author":"K Rickels","year":"1990","unstructured":"Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47(10):899\u2013907.","journal-title":"Arch Gen Psychiatry"},{"issue":"8339","key":"1354_CR151","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/S0140-6736(83)92355-3","volume":"1","author":"P Tyrer","year":"1983","unstructured":"Tyrer P, Owen R, Dawling S. Gradual withdrawal of diazepam after long-term therapy. Lancet. 1983;1(8339):1402\u20136.","journal-title":"Lancet"},{"issue":"3","key":"1354_CR152","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00213-002-1376-8","volume":"167","author":"C de las Cuevas","year":"2003","unstructured":"de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more \u201cbehavioral\u201d addiction than dependence. Psychopharmacol. 2003;167(3):297\u2013303.","journal-title":"Psychopharmacol"},{"issue":"1","key":"1354_CR153","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11920-015-0642-5","volume":"18","author":"M Lader","year":"2016","unstructured":"Lader M, Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. Curr Psychiatry Rep. 2016;18(1):8.","journal-title":"Curr Psychiatry Rep"},{"key":"1354_CR154","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/bmj.283.6292.643","volume":"283","author":"H Petursson","year":"1981","unstructured":"Petursson H, Lader MH. Withdrawal from long-term benzodiazepine treatment. Br Med J. 1981;283:634\u20135.","journal-title":"Br Med J"},{"key":"1354_CR155","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(84)92075-0","volume":"2","author":"SM Murphy","year":"1984","unstructured":"Murphy SM, Owen RT, Tyrer PJ. Withdrawal symptoms after six week\u2019s treatment with diazepam. Lancet. 1984;2:1389.","journal-title":"Lancet"},{"issue":"11","key":"1354_CR156","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","volume":"89","author":"H P\u00e9tursson","year":"1994","unstructured":"P\u00e9tursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455\u20139.","journal-title":"Addiction"},{"key":"1354_CR157","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.mehy.2018.06.019","volume":"118","author":"S LaCorte","year":"2018","unstructured":"LaCorte S. How chronic administration of benzodiazepines leads to unexplained chronic illnesses: a hypothesis. Med Hypotheses. 2018;118:59\u201367.","journal-title":"Med Hypotheses"},{"issue":"4","key":"1354_CR158","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0165-0327(92)90109-j","volume":"24","author":"A Holton","year":"1992","unstructured":"Holton A, Riley P, Tyrer P. Factors predicting long-term outcome after chronic benzodiazepine therapy. J Affect Disord. 1992;24(4):245\u201352. https:\/\/doi.org\/10.1016\/0165-0327(92)90109-j.","journal-title":"J Affect Disord"},{"key":"1354_CR159","volume-title":"The benzodiazepines crisis: an overview of the down-side of an overused drug class","author":"S Wright","year":"2020","unstructured":"Wright S. Benzodiazepine withdrawal: clinical aspects. In: Peppin J, Raffa R, Pergolizzi J, Wright S, editors. The benzodiazepines crisis: an overview of the down-side of an overused drug class. New York: Oxford University Press; 2020."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01354-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T02:12:05Z","timestamp":1620267125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01354-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":159,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01354-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}